Author

M. V. Hull

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 6 Approach:experimental assay· 6 Organism:human· 2 Research Focus:benchmarking· 1 Assay:proteomics· 1

Frequent Co-Authors

E. Chen· 5 shared A. K. Chatterjee· 2 shared C. W. McNamara· 2 shared T.-T. Nguyen· 2 shared A. Chatterjee· 1 shared A. Garcia-Sastre· 1 shared A. I. Su· 1 shared A. K. Gupta· 1 shared

Activity by Year

2019-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

E. Chen

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Identification of Potent Small Molecule Inhibitors of SARS-CoV-2 Entry

S. Jablonski, H. Mou, Y. Otsuka, J. Jablonski, R. S. Adcock, L. Batra, D. Chung, C. Rood, I. M. de Vera, R. Rahaim, S. Ullah, X. Yu, T.-T. Nguyen, M. V. Hull, E. Chen, , T. Spicer

This study identifies small molecule inhibitors of SARS-CoV-2 entry through high-throughput screening and validates Calpeptin as a potent inhibitor of SARS-CoV-2 and some variants.

bioRxiv · Aug 5, 2021Microbiology

Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19

M. A. Bakowski, N. Beutler, E. Chen, T.-T. H. Nguyen, M. G. Kirkpatrick, M. Parren, L. Yang, J. Ricketts, A. K. Gupta, M. V. Hull, P. G. Schultz, D. R. Burton, A. K. Chatterjee, C. W. McNamara, T. F. Rogers

The paper identifies 66 compounds that inhibit SARS-CoV-2 replication and 24 that synergize with remdesivir, suggesting potential oral drug repositioning candidates for COVID-19.

Nature Communications · Jun 3, 2021Peer-reviewedMicrobiology

Chemical inhibition of ENL/AF9 YEATS domains in acute leukemia

L. Garnar-Wortzel, T. R. Bishop, S. Kitamura, N. Milosevich, J. N. Asiaban, X. Zhang, Q. Zheng, E. Chen, A. R. Ramos, C. J. Ackerman, E. N. Hampton, A. K. Chatterjee, T. S. Young, M. V. Hull, K. B. Sharpless, , M. A. Erb

This study identifies a potent inhibitor of the ENL/AF9 YEATS domain and demonstrates its selective suppression of ENL-dependent leukemia genes.

bioRxiv · Dec 1, 2020Cancer Biology

Discovery of repurposing drug candidates for the treatment of diseases caused by pathogenic free-living amoebae

C. Rice, B. L. Colon, E. Chen, M. V. Hull, D. Kyle

This study identifies 58 potent drug candidates for treating diseases caused by pathogenic free-living amoebae through high-throughput screening of a compound library.

bioRxiv · May 13, 2020Microbiology

A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals

L. Riva, S. Yuan, X. Yin, L. Martin-Sancho, N. Matsunaga, S. Burgstaller, L. Pache, P. De Jesus, M. V. Hull, M. Chang, J. F. W. Chan, J. Cao, V. Kwok-Man Poon, K. Herbert, T.-T. Nguyen, , S. Chanda

This study identifies 30 known drugs that inhibit SARS-CoV-2 replication, with six showing effective concentrations likely to be therapeutic in patients.

bioRxiv · Apr 16, 2020 · PreprintMicrobiology

High-throughput screening of the ReFRAME library identifies potential drug repurposing candidates for Trypanosoma cruzi

J. A. Bernatchez, E. Chen, M. V. Hull, C. W. McNamara, J. H. McKerrow, J. L. Siqueira-Neto

The paper screens 12,000 compounds from the ReFRAME library against Trypanosoma cruzi, identifying 7 with potent in vitro activity and therapeutic index ≥10.

bioRxiv · Dec 11, 2019Microbiology